Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Fady T. Botros's publication output changed over time?
ScholarIQpublication output · 2005–2023
Output grew0% over the shown period — from 1 works in 2005 to 1 in 2023.
1
1
1
1
2
1
1
2
1
1
2005200820092011201220162018201920202023
What are the most-cited papers on Fady T. Botros?
ScholarIQmost cited works
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
Katherine R Tuttle, Mark Lakshmanan, Brian Rayner, Robert S. Busch, Alan G. Zimmermann, D. Bradley Woodward, Fady T. Botros
The Lancet Diabetes & Endocrinology. 2018645 Citations
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais, Rafael Díaz, Mark Lakshmanan, Prem Pais, Jeffrey L. Probstfield, Fady T. Botros, Matthew C. Riddle, Lars Rydén, Denis Xavier, Charles Atisso, Leanne Dyal, Stephanie Hall, Rao Ps, G.C. Wong, Álvaro Avezum, Jan Basile, Namsik Chung, Ignacio Conget, William C. Cushman, Edward Franek, Nicolae Hâncu, M Hanefeld, Shaun Holt, Petr Janský, Mátyás Keltai, Fernando Laņas, Lawrence A. Leiter, Patricio López‐Jaramillo, Ernesto Muñoz, Valdis Pīrāgs, Nana Pogosova, Peter Raubenheimer, Jonathan E. Shaw, Wayne Huey‐Herng Sheu, Theodora Temelkova‐Kurktschiev, Mercedes Abella, Andrea Alebuena, Sandra Almagro, Eduardo Amoroso, Paula Anadon, Elizabeth Andreu, Guillermo Aristimuño, Maria Arzadun, María Antonietta Barbieri, Raúl Barcudi, Ines Bartolacci, Gabriel Bolobanich, Anselmo P. Bordonava, Miguel Bustamante Labarta, B. Bustos, Alberto Caccavo, Alejandra Camino, María del Rocío Cantero, Maria Carignano, Luis R Cartasegna, Marcela Cipullo, Víctor Commendatore, Victoria Conosciuto, Osvaldo Costamagna, Claudia A. Crespo, Jose Cuello, Carlos Alberto Cuneo, Sandra Cusimano, Sofia Dean, Claudio Fabián Dituro, Andrea Domínguez, Miguel Farah, Alberto Fernandez, Florencia Fernandez, Adriana Cristina Ferrari, Patricia Flammia, José Antonio Fuentealba, Karina Beatriz Gallardo, C. Perez Garcia, Ruben Garcia Duran, Marcelo Garrido, Rodolfo Gavícola, Claudio Gerbaudo, Graciela Gilli, Ana Paula Giotto, Pedro Godoy Bolzán, Oscar Gómez Vilamajó, Fernando Guerlloy, Cristian Guridi, Narcisa Gutierrez Garrido, Eduardo Hasbani, Sonia Hermida, Miguel Hominal, Adrian D. Hrabar, Adrián Ingaramo, Alejandra Izzicupo, Mario Krynski, Mariana Lagrutta, Paulina Virginia Lanchiotti, Maria Langhe, Veronica Leonard, Javier Llanos, Ricardo López Santi
The Lancet. 2019638 CitationsOPEN ACCESS
Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program
Johan Jendle, George Grunberger, Thomas Blevins, Francesco Giorgino, Ryan T. Hietpas, Fady T. Botros
S83251063. 2016155 CitationsOPEN ACCESS
The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial
Hertzel C. Gerstein, Robert G. Hart, Helen M. Colhoun, Rafael Díaz, Mark Lakshmanan, Fady T. Botros, Jeffrey L. Probstfield, Matthew C. Riddle, Lars Rydén, Charles Atisso, Leanne Dyal, Stephanie Hall, Álvaro Avezum, Jan Basile, Ignacio Conget, William C. Cushman, Nicolae Hâncu, M Hanefeld, Petr Janský, Mátyás Keltai, Fernando Laņas, Lawrence A. Leiter, Patricio López‐Jaramillo, Ernesto Muñoz, Nana Pogosova, Peter Raubenheimer, Jonathan E. Shaw, Wayne Huey‐Herng Sheu, Theodora Temelkova‐Kurktschiev
The Lancet Diabetes & Endocrinology. 2020147 Citations
Tadalafil for the Treatment of Pulmonary Arterial Hypertension
Ronald J. Oudiz, Bruce H. Brundage, Nazzareno Galiè, Hossein Ardeschir Ghofrani, Gérald Simonneau, Fady T. Botros, Melanie Chan, Anthony Beardsworth, Robyn J. Barst
Journal of the American College of Cardiology. 2012145 Citations
Related on ScholarIQ
Eli Lilly (United States)
Institution
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
Paper
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
Paper
Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program
Paper
The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial
Paper
Tadalafil for the Treatment of Pulmonary Arterial Hypertension
Paper